Harrow Health Inc

Change company Symbol lookup

Select an option...

HROW Harrow Health Inc

WRLD World Acceptance Corp

CWD CaliberCos Inc

LNTH Lantheus Holdings Inc

DFIN Donnelley Financial Solutions Inc

SY So-Young International Inc

GOTU Gaotu Techedu Inc

SGDVV Safe & Green Development Corp

GLBZ Glen Burnie Bancorp

PHAR Pharming Group NV

Go

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the second quarter and six months ended June 30, 2023. The Company also posted its second quarter Letter to Stockholders and corporate presentation to...(BusinessWire)

Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 4.41% and 2.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?(Zacks)

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX(R) (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone...(BusinessWire)

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company will also...(BusinessWire)

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 per share for aggregate gross proceeds of...(BusinessWire)

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. ("Santen") under which Harrow will acquire certain U.S. and Canadian commercial rights...(BusinessWire)

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance: Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second...(BusinessWire)

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced a proposed underwritten registered public offering of its common stock, subject to market and certain other conditions. Harrow expects to grant the underwriters a...(BusinessWire)

--VEVYE(R) is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) Dosing Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Novaliq GmbH, a German biopharmaceutical company focusing on first- and...(BusinessWire)

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Harrow Health (HROW) and Disc Medicine (IRON).(Zacks)

We have narrowed our search to five stocks that have provided more than 50% returns year to date with more upside left. These are: CRD.A, REPX, UVE, ASUR and HROW. (Zacks)